KD Logo

Citigroup analysts upgrades a Buy rating for Quest Diagnostics, Inc. (DGX)

Quest Diagnostics, Inc.’s filing revealed that its SVP & Chief Commercial Officer DELANEY MARK E unloaded Company’s shares for reported $60094.0 on Jul 24 ’24. In the deal valued at $143.08 per share,420 shares were sold. As a result of this transaction, DELANEY MARK E now holds 5,019 shares worth roughly $0.73 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Then, KUPPUSAMY KARTHIK sold 1,760 shares, generating $246,400 in total proceeds. Upon selling the shares at $140.00, the SVP, Clinical Solutions now owns 13,435 shares.

Before that, PREVOZNIK MICHAEL E sold 5,611 shares. Quest Diagnostics, Inc. shares valued at $706,313 were divested by the SVP & General Counsel at a price of $125.88 per share. As a result of the transaction, PREVOZNIK MICHAEL E now holds 38,478 shares, worth roughly $5.61 million.

Citigroup upgraded its Quest Diagnostics, Inc. [DGX] rating to a Buy from a a Neutral in a research note published on July 10, 2024; the price target was increased to $165 from $145. A number of analysts have revised their coverage, including Leerink Partners’s analysts, who began to cover the stock in late February with a ‘”a Market perform”‘ rating. Jefferies also remained covering DGX and has increased its forecast on February 07, 2024 with a “Buy” recommendation from previously “Hold” rating. Barclays started covering the stock on January 03, 2024. It rated DGX as “an Equal weight”.

Price Performance Review of DGX

On Monday, Quest Diagnostics, Inc. [NYSE:DGX] saw its stock fall -2.86% to $145.79. Over the last five days, the stock has gained 2.57%. Quest Diagnostics, Inc. shares have risen nearly 5.74% since the year began. Nevertheless, the stocks have risen 6.66% over the past one year. While a 52-week high of $151.78 was reached on 08/02/24, a 52-week low of $119.59 was recorded on 02/01/24. SMA at 50 days reached $141.56, while 200 days put it at $134.70. A total of 1.21 million shares were traded, compared to the trading of 1.02 million shares in the previous session.

Levels Of Support And Resistance For DGX Stock

The 24-hour chart illustrates a support level at 143.59, which if violated will result in even more drops to 141.39. On the upside, there is a resistance level at 149.27. A further resistance level may holdings at 152.75. The Relative Strength Index (RSI) on the 14-day chart is 53.94, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 2.54, which suggests price will go up in the next trading period. Percent R suggests that price movement has been low at 42.57%. Stochastics%K at 74.23% indicates the stock is a holding.

Most Popular